What is the appropriate management for a 35-year-old male patient presenting with hypercalcemia, hypophosphatemia, low vitamin D levels, and osteolytic lesions in both hands?

Diagnostic Evaluation and Management of Hypercalcemia with Osteolytic Lesions in a Young Adult

This presentation strongly suggests malignancy-associated hypercalcemia with osteolytic bone disease, requiring urgent diagnostic workup and aggressive treatment.

The combination of hypercalcemia, hypophosphatemia, low vitamin D, and bilateral hand osteolytic lesions in a 35-year-old male is highly concerning for malignancy-related hypercalcemia rather than primary hyperparathyroidism 1, 2. Malignancy accounts for most inpatient hypercalcemia cases and is associated with poor prognosis, with median survival of approximately 1 month after discovery in patients with metastatic disease 1, 3.

---

Immediate Diagnostic Workup

Essential Laboratory Tests

Measure serum intact parathyroid hormone (PTH) immediately to distinguish PTH-dependent from PTH-independent hypercalcemia 1, 2. In this clinical context:

• Suppressed PTH (<20 pg/mL) with hypercalcemia confirms PTH-independent hypercalcemia, consistent with malignancy 1, 2
• Measure PTH-related protein (PTHrP), as elevated PTHrP with suppressed PTH indicates malignancy-associated hypercalcemia 1, 4
• Obtain both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels together, as their relationship provides critical diagnostic information 1, 3
• The low vitamin D (25-OH) reflects suppressed PTH, which normally drives conversion to active 1,25-dihydroxyvitamin D 1

Additional Required Tests

• Measure serum creatinine, BUN, and estimated GFR to assess renal function, as hypercalcemia can cause acute kidney injury 1, 3
• Check serum phosphorus (typically low-normal in primary hyperparathyroidism but variable in malignancy), albumin, and magnesium 1, 3
• Calculate corrected calcium using: Corrected calcium (mg/dL) = Total calcium + 0.8 × [4.0 - Serum albumin] 1, 3
• Measure ionized calcium (normal: 4.65-5.28 mg/dL) for definitive assessment 1

---

Imaging and Malignancy Evaluation

Radiographic Assessment

Obtain chest CT, abdominopelvic CT, and complete skeletal survey to identify primary malignancy and extent of metastatic disease 5. The bilateral hand osteolytic lesions suggest:

• Multiple myeloma (most common hematologic malignancy causing osteolytic lesions) 3
• Metastatic solid tumors (lung, breast, renal cell carcinoma) 1, 2
• Lymphoma with bone involvement 3

Tissue Diagnosis

• Bone marrow biopsy if multiple myeloma suspected (based on pattern of osteolytic lesions) 3
• Biopsy of accessible lesions for histopathologic confirmation 5

---

Immediate Management Algorithm

Step 1: Aggressive Hydration

Initiate intravenous normal saline immediately to correct hypovolemia and promote calciuresis 1, 3, 2:

• Target urine output of 100-150 mL/hour 3
• Administer boluses of 250-500 mL crystalloids every 15 minutes until rehydration achieved 3
• Monitor serum calcium, creatinine, and electrolytes every 6-12 hours during acute phase 3
• Avoid loop diuretics (furosemide) until complete volume repletion, then use only if renal or cardiac insufficiency present 3, 2

Step 2: Bisphosphonate Therapy

Administer zoledronic acid 4 mg IV infused over no less than 15 minutes as first-line pharmacologic therapy 1, 3, 2:

• Zoledronic acid is superior to pamidronate, normalizing calcium in 50% of patients by day 4 3
• Do not delay bisphosphonate therapy while awaiting complete rehydration 3
• Measure serum creatinine before administration and adjust dose if creatinine clearance <60 mL/min 3
• Monitor for hypocalcemia after treatment, though asymptomatic hypocalcemia does not require intervention 3

Step 3: Adjunctive Therapy if Severe

If calcium ≥14 mg/dL or patient has mental status changes, bradycardia, or hypotension 1:

• Consider calcitonin 100 IU subcutaneously or intramuscularly as temporizing measure for rapid calcium reduction (onset within hours) while awaiting bisphosphonate effect 3, 2, 6
• Calcitonin provides only short-term benefit (1-4 hours) with tachyphylaxis developing rapidly 4, 3

---

Malignancy-Specific Considerations

If Multiple Myeloma Confirmed

Hydration, zoledronic acid, and corticosteroids form the treatment approach 3:

• Continue bisphosphonate therapy for up to 2 years to reduce skeletal-related events by 41% 3
• Plasmapheresis should be used as adjunctive therapy if symptomatic hyperviscosity present 3
• Treat underlying malignancy urgently with chemotherapy, as this is definitive treatment 4, 3

If Solid Tumor Metastases

• PTHrP-mediated hypercalcemia carries poor prognosis with median survival approximately 1 month 1, 4
• Aggressive symptom management is priority 1, 4
• Treat underlying cancer when possible with chemotherapy or radiation 4, 3

---

Renal Impairment Considerations

If eGFR <60 mL/min/1.73m² or acute kidney injury present 3:

• Consider denosumab 120 mg subcutaneously instead of bisphosphonates, as it has lower rates of renal toxicity but higher risk of hypocalcemia 3
• For severe hypercalcemia with renal failure or oliguria, hemodialysis with calcium-free or low-calcium dialysate (1.25-1.50 mmol/L) may be necessary 4, 3
• Avoid NSAIDs and intravenous contrast media to prevent further renal deterioration 3

---

Critical Pitfalls to Avoid

• Do not assume primary hyperparathyroidism in a young patient with osteolytic lesions – this presentation demands malignancy workup 1, 2
• Do not order parathyroid imaging before confirming biochemical diagnosis – imaging is for surgical planning in confirmed PHPT, not diagnosis 1
• Do not supplement with vitamin D until hypercalcemia resolves and underlying cause identified 1, 4
• Do not restrict calcium intake excessively, as this can worsen bone disease once malignancy treatment begins 3
• Do not delay bisphosphonate therapy – temporary measures provide only 1-4 hours benefit with rebound hypercalcemia 4, 3

---

Monitoring and Follow-up

• Measure serum calcium 2-4 weeks after initiating treatment to assess response 4
• Perform baseline dental examination before continuing bisphosphonate therapy to prevent osteonecrosis of jaw 3
• Monitor renal function closely and discontinue bisphosphonates if unexplained albuminuria >500 mg/24 hours or serum creatinine increases >0.5 mg/dL 3
• Reassess for recurrent hypercalcemia, which indicates disease progression requiring oncology re-evaluation 3